MAXCYTE, INC.

MAXCYTE, INC. specializes in the development and manufacturing of advanced electroporation systems for scalable cellular transfection, enabling precise delivery of nucleic acids and therapeutics into mammalian cells. Their core capabilities center on proprietary non-viral delivery platforms, including the EXPERT ATX and EXPERT STX systems, which are engineered for high-efficiency, reproducible transfection in research, preclinical, and clinical manufacturing environments. The company demonstrates deep technical expertise in biophysical cell membrane modulation, instrument automation, and GMP-compatible process design, with a focus on enabling next-generation cell and gene therapies. Their differentiation lies in scalable, closed-system platforms that bridge laboratory innovation with clinical-grade production, supporting applications in immunotherapy, vaccine development, and ex vivo cell engineering. MAXCYTE has delivered solutions to the Department of Veterans Affairs and the Department of Health and Human Services, primarily supporting biomedical research and therapeutic development initiatives. These engagements reflect a pattern of collaboration with agencies focused on advancing cellular therapeutics and translational science, where reliable, high-throughput transfection technology is critical to accelerating discovery and regulatory-ready manufacturing. The company operates primarily under NAICS 541714 for biotechnology research and 334516 for analytical laboratory instrument manufacturing, positioning it at the intersection of life sciences R&D and precision instrumentation. MAXCYTE serves the cell and gene therapy market by providing mission-critical tools for academic, government, and biopharma laboratories engaged in functional genomics and cell-based drug development. As a small business structured as a 2L entity based in Rockville, Maryland, MAXCYTE maintains a focused government market presence with no federal certifications on record. Its geographic proximity to federal research hubs and biotech corridors enhances its ability to support mission-critical federal science and healthcare innovation initiatives.